Gene:
KCTD5
potassium channel tetramerisation domain containing 5

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Related Drugs?

Overview

Alternate Names:  potassium channel tetramerisation domain containing 5
Alternate Symbols:  FLJ20040
PharmGKB Accession Id: PA134923177

Details

Cytogenetic Location: chr16 : p13.3 - p13.3
GP mRNA Boundary: chr16 : 2732495 - 2759031
GP Gene Boundary: chr16 : 2722495 - 2762031
Strand: plus
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

LinkOuts

Entrez Gene:
54442
OMIM:
611285
RefSeq RNA:
NM_018992
RefSeq Protein:
NP_061865
RefSeq DNA:
AC_000059
AC_000148
NC_000016
NT_010393
NW_001838341
NW_926018
UniProtKB:
KCTD5_HUMAN (Q9NXV2)
Ensembl:
ENSG00000167977
GeneCard:
KCTD5
ALFRED:
LO054131O
HuGE:
KCTD5
Comparative Toxicogenomics Database:
54442
ModBase:
Q9NXV2
HumanCyc Gene:
HS09671
HGNC:
21423

Common Searches